Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY20 results · Jul–Sep 2019

Strides Pharma Science reported revenue from operations of ₹715.09 crore (down 2.4% from Q2 FY19) and net profit of ₹141.91 crore for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	715.09	732.63	−2.4%	685.80	+4.3%
Other income	12.99	7.73	+68.0%	10.25	+26.7%
Total income	728.08	740.36	−1.7%	696.05	+4.6%
Profit before share of associates & JVs and tax	161.68	6.97	23x	46.29	+249.3%
Share of profit/(loss) of associates & JVs	(21.25)	(12.30)		(17.81)
Net profit for the period	141.91	(8.70)	Turned profit	2.91	49x
Attributable to shareholders of the company	142.72	(12.01)	Turned profit	3.70	39x
EPS, basic (₹)	15.94	(1.34)	Turned profit	0.41	39x
Net margin (%)	19.8	-1.2		0.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	425.41	338.43	+25.7%	442.53	−3.9%
Other income	32.20	20.36	+58.2%	23.08	+39.5%
Total income	457.61	358.79	+27.5%	465.61	−1.7%
Profit before tax	58.22	(11.59)	Turned profit	30.34	+91.9%
Net profit for the period	47.00	(14.30)	Turned profit	24.68	+90.4%
EPS, basic (₹)	5.25	(1.60)	Turned profit	2.76	+90.2%
Net margin (%)	11.0	-4.2		5.6

Consolidated

Filed with BSE: 26 Oct 2019, 09:14 IST
Board meeting: 25 Oct 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 26 Oct 2019, 09:14 IST
Board meeting: 25 Oct 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE